Evidence map›Paper›PMID 14581177›Full record

ArticleBritish journal of pharmacology2003

Extended pharmacological profiles of rat P2Y2 and rat P2Y4 receptors and their sensitivity to extracellular H+ and Zn2+ ions.

Scott S Wildman, Robert J Unwin, Brian F King

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 144 citations in OpenAlex.

  1. Review
  2. Testosterone Enhances KInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. Functional P2XThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  5. P2 Receptors in Cardiac Myocyte Pathophysiology and Mechanotransduction.International journal of molecular sciences · 2020
    Review
  6. P2YInternational journal of molecular sciences · 2020
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Diadenosine tetraphosphate (ApPurinergic signalling · 2017
    Article
  14. Review
  15. Article
  16. P2Y receptors in Alzheimer's disease.Biology of the cell · 2015
    Review
  17. Review
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Scott S WildmanDepartment of Physiology, Centre for Nephrology, Royal Free Campus, Royal Free and University College Medical School, University College London, Rowland Hill Street, Hampstead, London NW3 2PF, UK.
Robert J Unwin
Brian F King
University College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1. Two molecularly distinct rat P2Y receptors activated equally by adenosine-5'-triphosphate (ATP) and uridine-5'-triphosphate (UTP) (rP2Y2 and rP2Y4 receptors) were expressed in Xenopus oocytes and studied extensively to find ways to pharmacologically distinguish one from the other. 2. Both P2Y subtypes were activated fully by a number of nucleotides. Tested nucleotides were equipotent at rP2Y4 (ATP=UTP=CTP=GTP=ITP), but not at rP2Y2 (ATP=UTP>CTP>GTP>ITP). For dinucleotides (ApnA, n=2-6), rP2Y4 was only fully activated by Ap4A, which was as potent as ATP. All tested dinucleotides, except for Ap2A, fully activated rP2Y2, but none were as potent as ATP. ATP gamma S and BzATP fully activated rP2Y2, whereas ATP gamma S was a weak agonist and BzATP was inactive (as an agonist) at rP2Y4 receptors. 3. Each P2Y subtype showed different sensitivities to known P2 receptor antagonists. For rP2Y2, the potency order was suramin>>PPADS= RB-2>TNP-ATP and suramin was a competitive antagonist (pA2, 5.40). For rP2Y4, the order was RB-2>>suramin>PPADS> TNP-ATP and RB-2 was a competitive antagonist (pA2, 6.43). Also, BzATP was an antagonist at rP2Y4 receptors. 4. Extracellular acidification (from pH 8.0 to pH 5.5) enhanced the potency of ATP and UTP by 8-10-fold at rP2Y4 but did not affect agonist responses at rP2Y2 receptors. 5. Extracellular Zn2+ ions (0.1-300 microM) coapplied with ATP inhibited agonist responses at rP2Y4 but not at rP2Y2 receptors. 6. These two P2Y receptors differ significantly in terms of agonist and antagonist profiles, and the modulatory activities of extracellular H+ and Zn2+ ions. These pharmacological differences will help to distinguish between rP2Y2 and rP2Y4 receptors, in vivo.

Indexed as

ProtonsAdenosine TriphosphateAnimalsDose-Response Relationship, DrugFemaleHydrogen-Ion ConcentrationKineticsMembrane PotentialsOocytesPatch-Clamp TechniquesPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsRatsReceptors, Purinergic P2SuraminUridine TriphosphateAdenosine TriphosphateProtonsPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsReceptors, Purinergic P2SuraminUridine TriphosphateZinc

Identifiers

PMID14581177
PMCPMC1574132
OpenAlexW2020880088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.